MedTrace Logo

Therapy Optimization in Multiple Sclerosis (MS)

NCT00819000 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2878

Last updated 2013-01-29

No results posted yet for this study

Summary

The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.

Conditions

Interventions

DRUG

Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b

MS therapies (listed above) used according to prescribers' instructions.

Sponsors & Collaborators

  • Teva Neuroscience, Inc.

    lead INDUSTRY

Principal Investigators

  • MerriKay Oleen-Burkey, PhD · Teva Neuroscience, Inc.

  • Howard Zwibel, MD · Neurologic Center of South Florida

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-12-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819000 on ClinicalTrials.gov